ITC to investigate Alvotech’s Humira biosimilar
27-01-2022
Judge refuses to block pay-for-delay law pending appeal
13-01-2020
casimiropt / Shutterstock.com
Buyers of AbbVie’s arthritis treatment Humira (adalimumab) have appealed against an Illinois judge’s decision to dismiss their class action antitrust suit to the US Court of Appeals for the Seventh Circuit.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
AbbVie, Humira, antitrust, competition, licensing deals, patent thickets, Pfizer, Sandoz, Mylan, biosimilars, Seventh Circuit
